Clinical Trial Update: Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update investigating an SGLT2 inhibitor for metabolic syndrome, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: The University of Hong Kong | Conditions: Metabolic Syndrome | Phase 3 | Status: ENROLLING_BY_INVITATION